Comparison between the ECG Outcomes of Metoprolol and Bisoprolol

Cardiovasc Hematol Agents Med Chem. 2023 Oct 31. doi: 10.2174/0118715257252349231018151957. Online ahead of print.

Abstract

Background: Beta-blockers are essential agents in the management of cardiovascular diseases, such as heart failure, acute myocardial infarction (MI), and cardiac arrhythmias. However, there are diurnal variations in the cardioprotective effects of the subgroups as a result of their different pharmacokinetic, pharmacodynamic, and pharmacogenetic profiles.

Objective: We aimed to compare metoprolol and bisoprolol in terms of electrocardiogram (ECG) outcomes.

Methods: A retrospective cross-sectional study was conducted at Prince Sultan Cardiac Center. The trial included 404 patients who met the inclusion criteria (204 in the metoprolol arm and 200 in the bisoprolol arm). Using case record forms that had already been created, information, such as patient demographics, medical histories, and treatment histories, was taken from their medical files. The most recent ECG records were also gathered. The ethical approval for this study was obtained from Qassim ethical committee (approval number: 45-44-902).

Results: There was no significant difference found between the patients in both arms in terms of baseline characteristics, age, or sex.

Conclusion: In this retrospective cross-sectional study, we have compared the effects of metoprolol and bisoprolol beta blockers on ECG changes. The findings have indicated no difference between metoprolol and bisoprolol groups in terms of all ECG readings, particularly PR/ms, QTC-ms, and ventricular rate. Further studies are required to confirm these findings.

Keywords: Beta blockers; ECG; bisoprolol; cardiovascular diseases; metoprolol; pharmacogenetic.